5- ((6- phenyl- (1,2,4)triazolo(4,3- b)pyridazin- 3- yl)methyl)isoquinolin- 1(2H)- one
a c-Met receptor tyrosine kinase inhibitor; structure in first source
Networked: 1
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Neoplasms (Cancer)
05/01/2013
- " Therefore, we suggest that KRC-327 may be a novel drug candidate with the therapeutic potential of targeting c-Met in human cancer." 05/01/2013
- " In xenograft animal models, KRC-327 significantly not only delayed tumor growth but also suppressed phosphorylation of c-Met and its signaling cascades as well as proliferation. " 05/01/2013
- " KRC-327 strongly suppressed the growth of c-Met over-expressed cancer cells (MKN-45, SNU-638, SNU-5), while not in c-Met absent cancer cell lines (MKN-1, SNU-1). " 05/01/2013
- " In the ligand-induced functional studies, KRC-327 inhibited proliferation of HGF-stimulated BxPC-3 cells, the migration of HGF-stimulated AGS cancer cells, and suppressed colony formation in HGF-stimulated U-87MG cells. " 05/01/2013
- " When we performed receptor tyrosine kinases (RTKs) array with 42 different phosphorylated-RTKs, KRC-327 strongly inhibited expression of activated c-Met in MKN-45 cancer cells. "
|
|
Related Drugs and Biologics